Scholarlink

<p>Axicabtagene ciloleucel (axi-cel) has demonstrated efficacy and safety in relapsed/refractory large B cell lymphoma (r/r LBCL). However, evidence from Asian populations remains limited.</p><p>This study evaluated patients with r/r LBCL who underwent leukapheresis for axi-cel between April 2023 and December 2025. Fifty-five patients were evaluable for safety, including 38 treated in the second-line setting (2L). CRS occurred in 53 (96%), with grade ≥ 3 in 6 (10%). ICANS occurred in 17 (31%), with grade ≥ 3 in 6 (11%). Compared with patients receiving third-line or later (3L +) treatment, 2L patients experienced higher rates of grade ≥ 3 CRS (13% vs. 6%) and any-grade ICANS (37% vs. 18%). Among the 55 patients, the overall response rate was 91%. After a median follow-up of 14.5&#xa0;months, the 1.5-year PFS and OS rates were 63.1% and 83.1%, respectively. 2L showed numerically higher PFS than 3L + (1.5-year PFS: 64.9% vs. 57.0%; HR: 1.75; <i>p</i> = 0.248). Multivariate analysis identified three independent risk factors for PFS: low peripheral blood CD8<sup>+</sup> naive T-cell count at leukapheresis, high metabolic tumor volume, and elevated LDH level at initiation of lymphodepleting chemotherapy. Axi-cel demonstrated substantial efficacy in Japanese patients with r/r LBCL. The 2L setting was associated with higher toxicity and numerically higher PFS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel

  • 期刊论文

  • 发表日期：

    2026年5月12日

查看全文
  • Risa Nishiyama,
  • Anna Hiratsuka,
  • Tetsuro Ochi,
  • Akiko Miyagi Maeshima,
  • Wataru Takeda,
  • Kimiteru Ito,
  • Yu Aruga,
  • Chiaki Ikeda,
  • Hirotaka Matsui,
  • Noriko Iwaki,
  • Suguru Fukuhara,
  • Wataru Munakata,
  • Shinichi Makita,
  • Koji Izutsu

摘要

Axicabtagene ciloleucel (axi-cel) has demonstrated efficacy and safety in relapsed/refractory large B cell lymphoma (r/r LBCL). However, evidence from Asian populations remains limited.

This study evaluated patients with r/r LBCL who underwent leukapheresis for axi-cel between April 2023 and December 2025. Fifty-five patients were evaluable for safety, including 38 treated in the second-line setting (2L). CRS occurred in 53 (96%), with grade ≥ 3 in 6 (10%). ICANS occurred in 17 (31%), with grade ≥ 3 in 6 (11%). Compared with patients receiving third-line or later (3L +) treatment, 2L patients experienced higher rates of grade ≥ 3 CRS (13% vs. 6%) and any-grade ICANS (37% vs. 18%). Among the 55 patients, the overall response rate was 91%. After a median follow-up of 14.5 months, the 1.5-year PFS and OS rates were 63.1% and 83.1%, respectively. 2L showed numerically higher PFS than 3L + (1.5-year PFS: 64.9% vs. 57.0%; HR: 1.75; p = 0.248). Multivariate analysis identified three independent risk factors for PFS: low peripheral blood CD8+ naive T-cell count at leukapheresis, high metabolic tumor volume, and elevated LDH level at initiation of lymphodepleting chemotherapy. Axi-cel demonstrated substantial efficacy in Japanese patients with r/r LBCL. The 2L setting was associated with higher toxicity and numerically higher PFS.